The notices it replaced
- Reissues: PAR-17-185 National Cooperative Drug/Device Discovery/Development Groups (U01)
- 2 steps back: PAR-14-184 National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U01)
Replaced by PAR-20-118.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $4,881,056 in first-year total cost, median $2,440,528.
Most frequent study sections
- Special Emphasis Panel[ZMH1 ERB-C (04)]1
- Special Emphasis Panel[ZMH1 ERB-C (05)]1
Most frequent institutions
- MOLECULAR NEUROIMAGING, LLC1
- YALE UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for Schizophrenia1U01MH121766-01 | ANTICEVIC, ALANKRYSTAL, JOHN H. | YALE UNIVERSITY, CT | $3,804,360 | ZMH1 |
| 2015 | A Program for Innovative PET Radioligand Development and Application - a translational toolbox for treatments for Mental Health1U01MH107803-01 · under PAR-14-184 | TAMAGNAN, GILLES D | MOLECULAR NEUROIMAGING, LLC, CT | $1,076,696 | ZMH1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.